Optimizing technology for cervical cancer screening in high-resource settings (Q36319941)

13 August 2017

Optimizing technology for cervical cancer screening in high-resource settings (English)

1 reference

13 August 2017

cervix uterine cancer

1 reference

Eduardo L Franco

3

0 references

author name string

Lyndsay A Richardson

series ordinal

1

1 reference

PMC publication ID

4659856

13 August 2017

Joseph Tota

series ordinal

2

1 reference

13 August 2017

1 May 2011

1 reference

Expert Review of Obstetrics and Gynecology

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

3

1 reference

13 August 2017

343-353

1 reference

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Using biomarkers as objective standards in the diagnosis of cervical biopsies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Cervical cancer prevention: new tools and old barriers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Currently approved prophylactic HPV vaccines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Integrating human papillomavirus vaccination in cervical cancer control programmes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

New approaches to cervical cancer screening in Latin America and the Caribbean

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus testing for primary cervical cancer screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Cervical cancer screening following prophylactic human papillomavirus vaccination

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

HPV and cervical cancer: screening or vaccination?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

2006 consensus guidelines for the management of women with abnormal cervical screening tests

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Risk assessment to guide the prevention of cervical cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Biomarkers in cervical cancer screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Chapter 7: Achievements and limitations of cervical cytology screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Chapter 2: The burden of HPV-related cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

A critical assessment of screening methods for cervical neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Report of the 2003 pan-Canadian forum on cervical cancer prevention and control.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Management of women who test positive for high-risk types of human papillomavirus: the HART study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Findings to date from the ASCUS-LSIL Triage Study (ALTS).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Chapter 13: Primary screening of cervical cancer with human papillomavirus tests

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The 2001 Bethesda System: terminology for reporting results of cervical cytology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003.

29 June 2018

1 reference

Reducing the burden of glandular carcinomas of the uterine cervix

21 January 2018

1 reference

Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women

21 January 2018

1 reference

Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial

21 January 2018

1 reference

Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus.

21 January 2018

1 reference

Human papillomavirus and cervical cancer

21 January 2018

1 reference

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

21 January 2018

1 reference

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

21 January 2018

1 reference

The health and economic effects of HPV DNA screening in The Netherlands

21 January 2018

1 reference

Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.

21 January 2018

1 reference

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

21 January 2018

1 reference

A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India

21 January 2018

1 reference

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

21 January 2018

1 reference

p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal.

21 January 2018

1 reference

Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study.

21 January 2018

1 reference

Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix

21 January 2018

1 reference

The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening

21 January 2018

1 reference

Human papillomavirus DNA testing for cervical cancer screening in low-resource settings

21 January 2018

1 reference

Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology.

21 January 2018

1 reference

Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.

21 January 2018

1 reference

Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru.

21 January 2018

1 reference

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

21 January 2018

1 reference

Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4659856

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

22 September 2018

1 reference

Further analysis of the ARTISTIC trial

21 January 2018

1 reference

Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico

21 January 2018

1 reference

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica

21 January 2018

1 reference

12 December 2020

Human papillomavirus testing for primary screening of cervical cancer precursors

1 reference

12 December 2020

Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix

1 reference

12 December 2020

Accuracy of conventional cytology: results from a multicentre screening study in India

1 reference

12 December 2020

Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India

1 reference

12 December 2020

The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia

1 reference

12 December 2020

A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia

1 reference

12 December 2020

Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia

1 reference

12 December 2020

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

1 reference

12 December 2020

Risk assessment to guide the prevention of cervical cancer

1 reference

12 December 2020

Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3

1 reference

12 December 2020

Screening for cervical cancer in the era of the HPV vaccine--the urgent need for both new screening guidelines and new biomarkers

1 reference

12 December 2020

Statement on HPV DNA test utilization

1 reference

12 December 2020

Trials comparing cytology with human papillomavirus screening

1 reference

12 December 2020

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

1 reference

12 December 2020

ACOG Practice Bulletin no. 109: Cervical cytology screening

1 reference

12 December 2020

Cytology versus HPV testing for cervical cancer screening in the general population.

1 reference

12 December 2020

Identifiers

DOI

10.1586/EOG.11.13

1 reference

13 August 2017

1 reference

PMC publication ID

4659856

13 August 2017

PubMed publication ID

26617667

1 reference

PMC publication ID

4659856